================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------
SCHEDULE 13G
(RULE 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED
PURSUANT TO RULES 13D-1(b), (c) AND (d) AND
AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)
-----------
(Amendment No. 1)*
ACADIA PHARMACEUTICALS INC.
- --------------------------------------------------------------------------------
(NAME OF ISSUER)
COMMON STOCK 004225108
- ------------------------------ ---------------------------------
(TITLE OF CLASS OF SECURITIES) (CUSIP NUMBER)
DECEMBER 31, 2007
- --------------------------------------------------------------------------------
(DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)
CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE
IS FILED:
[_] RULE 13D-1(b)
[_] RULE 13D-1(c)
[X] RULE 13D-1(d)
----------
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 or otherwise subject to the liabilities of that section of the Act but
shall be subject to all other provisions of the Act (however, see the Notes).
Continued on Following Pages
Page 1 of 6
================================================================================
- ------------------------------------------------ ----------------------------
CUSIP No. 004225108 13G Page 2 of 6
- ------------------------------------------------ ----------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS: NOMURA INTERNATIONAL PLC ON BEHALF
OF NOMURA PHASE4 VENTURES LP, NOMURA
PHASE4 GP LIMITED AND NOMURA PHASE4
VENTURES LIMITED
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:*
(A) [_]
(B) [X]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ENGLAND AND WALES
ORGANIZATION:
- --------------------------------------------------------------------------------
5 SOLE VOTING POWER: SHARES OF COMMON STOCK:
1,760,010
WARRANTS TO PURCHASE
COMMON STOCK: 549,752
NUMBER OF ---------------------------------------------------------------
SHARES 6 SHARED VOTING POWER: 0
BENEFICIALLY
OWNED BY ---------------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER: SHARES OF COMMON STOCK:
REPORTING 1,760,010
PERSON WITH WARRANTS TO PURCHASE
COMMON STOCK: 549,752
---------------------------------------------------------------
8 SHARED DISPOSITIVE POWER: 0
- --------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY SHARES OF COMMON STOCK:
OWNED BY EACH REPORTING PERSON: 1,760,010
WARRANTS TO PURCHASE
COMMON STOCK: 549,752
- --------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES:* [_]
- --------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 6.2%
- --------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON: CO, OO
- --------------------------------------------------------------------------------
ITEM 1. NAME OF ISSUER AND ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
(a) and (b) This Statement on Schedule 13G (the "Schedule 13G")
relates to the Common Stock, par value $0.0001 per share (the "Common Stock"),
of ACADIA Pharmaceuticals Inc., a Delaware corporation (the "Issuer"). The
address of the principal executive offices of the Issuer is 3911 Sorrento Valley
Boulevard, San Diego, CA 92121.
ITEM 2. NAME OF PERSON FILING
(a) Name of Persons Filing:
See Item 1 on the cover page. See also Schedule I.
(b) Address of Principal Business Office or, if None, Residence:
Nomura House
1 St Martins-le-Grand
London, EC1A 4NP
United Kingdom
(c), (d) and (e) For information with respect to citizenship of each
of the Reporting Persons, title of class of securities and CUSIP number for the
shares held by such persons, see the cover page above.
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B)
OR (C), CHECK WHETHER THE PERSON FILING IS:
Not applicable.
ITEM 4. OWNERSHIP
(a) - (c) These responses are as of December 31, 2007. The response
of the Reporting Persons to Items 5 through 11 on the Cover Sheet which relate
to the beneficial ownership of the Common Stock of the Issuer is incorporated
herein by reference. The percentage ownership of the reporting persons is based
on 37,517,092 shares comprised of 36,967,340 shares of Common Stock outstanding
as of October 31, 2007, as reported by the Issuer in its Form 10-Q for the
period ending September 30, 2007 and 549,752 shares of Common Stock, not yet
issued, underlying the warrant described on Schedule I.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
Not applicable.
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
Not applicable.
Page 3 of 6
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
See Schedule I.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
Not applicable.
ITEM 9. NOTICE OF DISSOLUTION OF GROUP
Not applicable.
ITEM 10. CERTIFICATION
(a) Not applicable.
(b) By signing below, the undersigned certifies that, to the best of
his or its knowledge and belief, the securities referred to above were not
acquired and are not held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and were not acquired
and are not held in connection with or as a participant in any transaction
having that purpose or effect.
[The remainder of this page intentionally left blank.]
Page 4 of 6
SIGNATURE
After reasonable inquiry and to the best of our knowledge and
belief, the undersigned certify that the information set forth in this statement
is true, complete and correct.
Date: February 12, 2008
NOMURA INTERNATIONAL PLC
By: /s/ Denise Pollard-Knight
------------------------------
Name: Denise Pollard-Knight
Title: Managing Director
Page 5 of 6
SCHEDULE I
This statement is being filed by Nomura International plc ("NI"), a public
limited company incorporated under the laws of England and Wales, on behalf of
itself and Nomura Phase4 Ventures LP ("NLP"), Nomura Phase4 GP Limited ("NGP")
and Nomura Phase4 Ventures Limited ("NVL") (collectively, the "Reporting
Persons"). Each of the Reporting Persons has the address of Nomura House, 1 St
Martins-le-Grand, London, EC1A 4NP, United Kingdom. NI owns directly all of the
stock of NVL. NVL owns directly all of the stock of NGP. NGP is the manager of
NLP.
NLP acquired 2,199,010 shares of Common Stock of the Issuer pursuant to that
certain Securities Purchase Agreement dated April 15, 2005 by and among the
Issuer and certain purchasers listed therein. During the period between December
31, 2006 and December 31, 2007 NLP sold 439,000 shares of Common Stock resulting
in the present holdings of 1,760,010 shares of Common Stock.
NI, NGP and NVL each disclaim beneficial ownership of the securities held
directly by NLP.
Page 6 of 6